Barclays Maintains Overweight on bluebird bio, Lowers Price Target to $8

Benzinga · 03/31 14:43
Barclays analyst Gena Wang maintains bluebird bio (NASDAQ:BLUE) with a Overweight and lowers the price target from $40 to $8.